Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for.
In multivariable analyses conducted by several groups, a post-therapy decline in prostate specific antigen was the most significant factor associated with survival of patients with relapsed prostate cancer. Contemporary combination regimens result in consistent declines in prostate-specific antigen in up to 40% of cases, along with objective tumour regression, and the improvement in cancer-related symptoms. It is, therefore, apparent that prostate cancers are not as resistant to treatment as previously believed.